Clinical practice guidelines for the use of colony-stimulating factors in cancer treatment: Implications for oncology nurses

European Journal of Oncology Nursing

Volumn 12, Issue 1, 2008, Pages 14-25

  Kearney, Nora ^a   Friese, Christopher ^b  

^a UNIVERSITY OF STIRLING   (United Kingdom)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Chemotherapy induced neutropenia; Clinical guidelines; Colony stimulating factors; Febrile neutropenia; Granulocyte colony stimulating factors; Prophylaxis

Indexed keywords

ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR;

ALGORITHM; CHEMICALLY INDUCED DISORDER; CLINICAL NURSING RESEARCH; DECISION TREE; DRUG ADMINISTRATION; DRUG MONITORING; EVIDENCE BASED MEDICINE; HUMAN; NEOPLASM; NEUTROPENIA; NURSE ATTITUDE; NURSING ASSESSMENT; ONCOLOGY NURSING; ORGANIZATION AND MANAGEMENT; PATIENT SELECTION; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT;

ALGORITHMS; ANTINEOPLASTIC AGENTS; CLINICAL NURSING RESEARCH; COLONY-STIMULATING FACTORS; DECISION TREES; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; EVIDENCE-BASED MEDICINE; HUMANS; NEOPLASMS; NEUTROPENIA; NURSE'S ROLE; NURSING ASSESSMENT; ONCOLOGIC NURSING; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT;

EID: 39149144484     PISSN: 14623889     EISSN: 15322122     Source Type: Journal    
DOI: 10.1016/j.ejon.2007.10.001     Document Type: Review

References (53)

1. Aapro M.S., Cameron D.A., Pettengell R., Bohlius J., Crawford J., Ellis M., et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. European Journal of Cancer 42 (2006) 2433-2453
2. American Society of Clinical Oncology. American Society of Clinical Oncology Guidelines Procedures Manual. Available online at: 〈http://www.asco.org/ac/1,1003,12-002562-00_18-0026185-00_19-00-00_20-001,00.asp〉. Accessed December 20, 2005.
3. Ardizzoni A., Favaretto A., Boni L., Baldini E., Castiglioni F., Antonelli P., et al. Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis-a Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) study. Journal of Clinical Oncology 23 (2005) 569-575
4. Bodey G.P., Buckley M., Sathe Y.S., and Freireich E.J. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Annals of Internal Medicine 64 (1966) 328-340
5. Bonadonna G., Moliterni A., Zambetti M., Daidone M.G., Pilotti S., Gianni L., and Valagussa P. 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. British Medical Journal 330 (2005) 217
6. Bonneterre J., Roche H., Kerbrat P., Bremond A., Fumoleau P., Namer M., et al. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. Journal of Clinical Oncology 23 (2005) 2686-2693
7. Budman D.R., Berry D.A., Cirrincione C.T., et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. Journal of the National Cancer Institute 90 (1998) 1205-1211
8. Caggiano V., Weiss R.V., Rickert T.S., and Linde-Zwirble W.T. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 103 (2005) 1916-1924
9. Cordonnier C., Herbrecht R., Buzyn A., et al. Risk factors for Gram-negative bacterial infections in febrile neutropenia. Haematologica 90 (2005) 1102-1109
10. Cosler L.E., Calhoun E.A., Agboola O., and Lyman G.H. Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy. Pharmacotherapy 24 (2004) 488-494
11. Crawford J., Ozer H., Stoller R., Johnson D., Lyman G., Tabbara I., et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. New England Journal of Medicine 325 (1991) 164-170
12. Crawford J., Dale D.C., and Lyman G.H. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 100 (2004) 228-237
13. Crawford, J., Wolff, D., Culakova, E., Poniewierski, M.S., Selby, C., Dale, D.C., Lyman, G.H., for the ANC Study Group, 2004b. First-cycle risk of severe and febrile neutropenia in cancer patients receiving systemic chemotherapy: results from a prospective nationwide study. Poster presented at Annual Meeting of the American Society of Hematology, December 4-7, 2004, San Diego, CA, USA (Abstract 2210).
14. Crawford, J., Althaus, B., Armitage, J., Balducci, L., Blayney, D.W., Cataland, S.R., et al., 2006. Myeloid Growth Factors in Cancer Treatment: The National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, Version 1.2006. Available online at: 〈http://www.nccn.org〉. Accessed October 12, 2006.
15. Dale D.C., McCarter G.C., Crawford J., and Lyman G.H. Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. Journal of the National Comprehensive Cancer Network 1 (2003) 440-454
16. De Bock, R., Cometta, A., Kern, W., Aoun, M., Caballero, D., Engelhard, D., Schaffner, A., Galazzo, M., Paesmans, M., vanDenbergh, M., Viscoli, C., for the International Antimicrobial Therapy Group of the EORTC, et al., 2001. Incidence of single agent gram-negative bacteremias in neutropenic cancer patients in EORTC-IATG trials of empirical therapy for febrile neutropenia. Presented at 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19, 2001, Chicago, IL, USA (Abstract L-773).
17. Donohue R. Development and implementation of a risk assessment tool for chemotherapy-induced neutropenia. Oncology Nursing Forum 33 (2006) 347-352
18. Doyle A. Prechemotherapy assessment of neutropenic risk. Oncology, Nurse Edition 20 10 Suppl. 7 (2006). http://cancernetwork.com/nurses-edition Available online at: 〈http://cancernetwork.com/nurses-edition〉. Accessed November 24, 2006
19. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
20. Epelbaum R., Faraggi D., Ben-Arie Y., Ben-Shahar M., Haim N., Ron Y., et al. Survival of diffuse large cell lymphoma: a multivariate analysis including dose intensity variables. Cancer 66 (1990) 1124-1129
21. Green M.D., Koelbl H., Baselga J., Galid A., Guillem V., Gascon P., et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Annals of Oncology 14 (2003) 29-35
22. Gáytan-Martinez J., Mateos-Garcia E., Sánchez-Cortes E., González-Llaven J., Casanova-Cardiel L.J., and Fuentes-Allen J.L. Microbiological findings in febrile neutropenia. Archives of Medical Research 31 (2000) 388-392
23. Hackshaw A., Sweetenham J., and Knight A. Are prophylactic haematopoietic growth factors of value in the management of patients with aggressive non-Hodgkin's lymphoma?. British Journal of Cancer 90 (2004) 1302-1305
24. Holmes F.A., O'Shaughnessy J.A., Vukelja S., Jones S.E., Shogan J., Savin M., et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. Journal of Clinical Oncology 20 (2002) 727-731
25. Kuderer N.M., Crawford J., Dale D.C., and Lyman G.H. Meta-analysis of prophylactic granulocyte colony-stimulating factor in cancer patients receiving chemotherapy. Journal of Clinical Oncology 23 16S (2005) 758s (Abstract 8117)
26. Kuderer N.M., Dale D.C., Crawford J., Cosler L.E., and Lyman G.H. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106 (2006) 2258-2266
27. Kwak L.W., Halpern J., Olshen R.A., and Horning S.J. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. Journal of Clinical Oncology 8 (1990) 963-977
28. Leese B. The costs of treating febrile neutropenia in six UK hospitals. European Journal of Cancer 29A Suppl. 7 (1993) S15-S18
29. Lenhart C. Relative dose intensity: improving cancer treatment and outcomes. Oncology Nursing Forum 32 (2005) 757-764
30. Link B.K., Budd G.T., Scott S., Dickman E., Paul D., Lawless G., et al. Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: current patterns of care. Cancer 92 (2001) 1354-1367
31. Lyman G.H. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. Journal of the National Comprehensive Cancer Network 3 (2005) 557-571
32. Lyman G.H., and Kuderer N.M. Epidemiology of febrile neutropenia. Supportive Cancer Therapy 1 (2003) 23-25
33. Lyman G.H., Kuderer N.M., and Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. The American Journal of Medicine 112 (2002) 406-411
34. Lyman G.H., Dale D.C., and Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. Journal of Clinical Oncology 21 (2003) 4524-4531
35. Lyman G.H., Dale D.C., Friedberg J., Crawford J., and Fisher R.I. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. Journal of Clinical Oncology 22 (2004) 4302-4311
36. Lyman G.H., Kuderer N.M., Crawford J., Wolff D.A., Culakova E., Poniewierski M.S., et al. Prospective validation of a risk model for first cycle neutropenic complications in patients receiving cancer chemotherapy. Journal of Clinical Oncology 24 (2006) (Abstract 8561)
37. López A., Alonso J.D., Gómez-Codina J., Novo A., Herrera C., Lara N., et al., on behalf of the ENIA Study Group. Febrile neutropenia in lymphoma patients is associated with substantial resource use and healthcare costs in clinical practice in Spain. Blood 108 (2006) (Abstract 5512)
38. Maxwell C., and Stein A. Implementing evidence-based guidelines for preventing chemotherapy-induced neutropenia: from paper to clinical practice. Community Oncology 3 (2006) 530-536
39. Maxwell, C., Winkler, L., Lottenberg, M., 2002. Nurse-driven neutropenia management guidelines: improving patient outcomes through evidence-based practice. Presented at 27th Annual Congress of Oncology Nursing Society, April 18-21, 2002, Washington, DC, USA (Abstract 171).
40. Mayordomo J.I., Castellanos J., Pernas S., Ruiz-Borrego M., Velasco A., Frau A., et al., on behalf of the ENIA Study Group. Cost analysis of febrile neutropenia management of breast cancer patients in clinical practice in Spain. Annals of Oncology 17 Suppl. 9 (2006) (Abstract 617P)
41. Michelson, J.L., Shedlock, K., Bergen, S., Doherty, E., Emens, C., Parrone, M.K., 2002. Using evidence to implement a collaborative neutropenia management protocol for improving chemotherapy delivery. Presented at 27th Annual Congress of Oncology Nursing Society, April 18-21, 2002, Washington, DC, USA (Abstract 169).
42. Oncology Nursing Society, 2006. Evidence Based Practice Resource Area. Available online at: 〈http://onsopcontent.ons.org/toolkits/evidence/index.shtml〉. Accessed October 13, 2006.
43. Pettengell, R., Bosly, A., Szucs, T.D., Jackisch, C., Leonard, R., Paridaens, R., et al. on behalf of the Impact of Neutropenia on Chemotherapy Study Group (INC-EU), 2006. Impact of febrile neutropenia and colony stimulating factor use on chemotherapy delivery in patients with lymphoma: results from the INC-EU prospective observational European neutropenia study. Poster presented at Annual Meeting of the American Society of Hematology, December 9-12, 2006, Orlando, FL, USA (Abstract 550723).
44. Picozzi V.J., Pohlman B.L., Morrison V.A., Lawless G.D., Lee M.W., Kerr R.O., et al. Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma. Oncology (Huntington, New York) 15 (2001) 1296-1306
45. Repetto L., Biganzoli L., Koehne C.H., Luebbe A.S., Soubeyran P., Tjan-Heijnen V.C., and Aapro M.S. EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer. European Journal of Cancer 39 (2003) 2264-2272
46. Sackett D.L., Rosenberg W.M., Gray J.A., Haynes R.B., and Richardson W.S. Evidence based medicine: what it is and what it isn't. British Journal of Cancer 312 (1996) 71-72
47. Smith T.J., Khatcheressian J., Lyman G.H., Ozer H., Armitage J.O., Balducci L., et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. Journal of Clinical Oncology 24 (2006) 3187-3205
48. Timmer-Bonte J.N., de Boo T.M., Smit H.J., Biesma B., Wilschut F.A., Cheragwandi S.A., et al. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch randomized phase III study. Journal of Clinical Oncology 23 (2005) 7974-7984
49. Trillet-Lenoir V., Green J., Manegold C., Von Pawel J., Gatzemeier U., Lebeau B., et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. European Journal of Cancer 29A (1993) 319-324
50. Vogel C.L., Wojtukiewicz M.Z., Carroll R.R., Tjulandin S.A., Barajas-Figueroa L.J., Wiens B.L., et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. Journal of Clinical Oncology 23 (2005) 1178-1184
51. White, N., Keehne-Miron, J., 2002. Assessing clinical outcomes in breast cancer patients in a community-based cancer center. Presented at 27th Annual Congress of Oncology Nursing Society, April 18-21, 2002, Washington, DC, USA (Abstract 102).
52. White N., Maxwell C., Michelson J., and Bedell C. Protocols for managing chemotherapy-induced neutropenia in clinical oncology practices. Cancer Nursing 28 (2005) 62-69
53. Zitella L.J., Friese C.R., Hauser J., Gobel B.H., Woolery M., O'Leary C., and Andrews F.A. Putting evidence into practice: prevention of infection. Clinical Journal of Oncology Nursing 10 (2006) 739-750